CXCR7 antagonist-1 (hydrochloride)

• UNSPSC Description:

  CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128)[1].

• Target Antigen:

  CXCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cxcr7-antagonist-1-hydrochloride.html

• Solubility:

  DMSO : 350 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=NN(C2=CC=C(C=C2)F)C=C1)N[C@@H]3CN(CC3)C4=NC=CN5C4=CC=C5.[H]Cl

• Molecular Weight:

  426.87

• References & Citations:

  [1]Junfa Fan, et al. Cxcr7 antagonists. Patent WO2014085490A1.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2990472-61-0